MYC and diffuse large B-cell lymphoma: studied 211 patients with stage I/II DLBCL who received R‐CHOP‐like regimen with or without RT and showed that 33 (16%) had double expression of MYC and BCL2, and the double expression of MYC and BCL2 did not correlate with poor PFS (p = 0.552) and OS (p = 0.439) in their patients.35